Browsing Tag
blood cancer treatment
5 posts
Bristol Myers Squibb Gains U.S. FDA Approval to Remove REMS Programs and Ease Monitoring Rules for Breyanzi and Abecma Cell Therapies
Bristol Myers Squibb gains U.S. FDA approval to remove REMS and reduce monitoring for Breyanzi and Abecma cell therapies, expanding access for blood cancer patients.
Janssen Pharmaceutical’s IMBRUVICA and Rituximab combo wins FDA approval for waldenström’s macroglobulinemia treatment
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has received approval from the US Food and Drug Administration…
Cantex Pharmaceuticals’ CX-01 receives FDA fast track designation in acute myeloid leukemia
Cantex Pharmaceuticals, a Florida-based biotechnology company, has achieved a significant milestone by securing Fast Track designation from the…
Cyclacel Pharmaceuticals’ sapacitabine fails to meet primary endpoint in Phase 3 blood cancer trial
Cyclacel Pharmaceuticals, a New Jersey-based biopharmaceutical company, announced that its experimental blood cancer drug, sapacitabine (CYC682), did not…
Pfizer’s inotuzumab ozogamicin gains FDA priority review in acute lymphoblastic leukemia
Pfizer Inc. has received a priority review designation from the U.S. Food and Drug Administration (FDA) for its…